循环肿瘤浆细胞高水平是新诊断适合移植多发性骨髓瘤侵袭性疾病的关键标志
本研究基于多中心随机FORTE试验,用两管单平台流式细胞术在诊断时分析401例适合移植的新诊断多发性骨髓瘤患者的循环肿瘤浆细胞(CTC),中位随访50个月。确定CTC最佳截断值为0.07%(约5个细胞/µL),CTC高者无进展生存期和总生存期均显著缩短,而微小残留病(MRD)阴性是唯一削弱其不良预后影响的因素。
要点
- CTC最佳截断值为0.07%(约5个细胞/µL),CTC高者4年PFS为38%对69%、4年OS为68%对92%。
- 多因素分析中CTC高者的PFS风险比为2.61(95%CI 1.49~2.97,P<.001),OS风险比为2.61(95%CI 1.49~4.56,P<.001)。
- CTC水平而非骨髓浆细胞水平影响结局,MRD阴性是唯一削弱CTC高不良影响的交互因素(交互P=.039)。
核心结论
- 在新诊断多发性骨髓瘤中,CTC高于最佳截断值代表一个易于评估、稳健且独立的高危因素。
- 获得MRD阴性是调节CTC高不良预后影响的最重要因素。
研究设计与样本
- 多中心随机FORTE临床试验(ClinicalTrials.gov标识:NCT02203643)纳入的患者。
- 诊断时用两管单平台流式细胞术分析CTC(灵敏度4×10-5),共分析401例患者。
- MRD用第二代多参数流式细胞术评估(灵敏度10-5)。
- 中位随访50个月(四分位距45~54个月)。
主要发现
- CTC百分比与骨髓浆细胞百分比呈弱相关(r=0.38)。
- 通过多因素Cox回归以Harrell C统计量最大化确定CTC最佳截断值为0.07%(约5个细胞/µL,C指数0.64)。
- 多因素分析中CTC高对CTC低患者PFS显著更短(风险比2.61,95%CI 1.49~2.97,P<.001;4年PFS 38%对69%)。
- 多因素分析中CTC高对CTC低患者OS显著更短(风险比2.61,95%CI 1.49~4.56,P<.001;4年OS 68%对92%)。
- CTC水平而非骨髓浆细胞水平影响结局;唯一削弱CTC高不良影响的因素是获得MRD阴性(交互P=.039)。
关键数值与推荐
- CTC最佳截断值为0.07%(约5个细胞/µL,C指数0.64)。
- CTC高对CTC低的PFS风险比为2.61(95%CI 1.49~2.97,P<.001),4年PFS为38%对69%。
- CTC高对CTC低的OS风险比为2.61(95%CI 1.49~4.56,P<.001),4年OS为68%对92%。
- CTC百分比与骨髓浆细胞百分比相关系数r=0.38。
- MRD阴性与CTC高交互作用的P=.039。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High levels of circulating tumor plasma cells (CTC-high) in patients with multiple myeloma are a marker of aggressive disease. We aimed to confirm the prognostic impact and identify a possible cutoff value of CTC-high for the prediction of progression-free survival (PFS) and overall survival (OS), in the context of concomitant risk features and minimal residual disease (MRD) achievement. METHODS: CTC were analyzed at diagnosis with two-tube single-platform flow cytometry (sensitivity 4 × 10-5) in patients enrolled in the multicenter randomized FORTE clinical trial (ClinicalTrials.gov identifier: NCT02203643). MRD was assessed by second-generation multiparameter flow cytometry (sensitivity 10-5). We tested different cutoff values in series of multivariate (MV) Cox proportional hazards regression analyses on PFS outcome and selected the value that maximized the Harrell's C-statistic. We analyzed the impact of CTC on PFS and OS in a MV analysis including baseline features and MRD negativity. RESULTS: CTC analysis was performed in 401 patients; the median follow-up was 50 months (interquartile range, 45-54 months). There was a modest correlation between the percentage of CTC and bone marrow plasma cells (r = 0.38). We identified an optimal CTC cutoff of 0.07% (approximately 5 cells/µL, C-index 0.64). In MV analysis, CTC-high versus CTC-low patients had significantly shorter PFS (hazard ratio, 2.61; 95% CI, 1.49 to 2.97, P < .001; 4-year PFS 38% v 69%) and OS (hazard ratio, 2.61; 95% CI, 1.49 to 4.56; P < .001; 4-year OS 68% v 92%). The CTC levels, but not the bone marrow plasma cell levels, affected the outcome. The only factor that reduced the negative impact of CTC-high was the achievement of MRD negativity (interaction P = .039). CONCLUSION: In multiple myeloma, increasing levels of CTC above an optimal cutoff represent an easy-to-assess, robust, and independent high-risk factor. The achievement of MRD negativity is the most important factor that modulates their negative prognostic impact.
引用
- Bertamini L, Oliva S, Rota-Scalabrini D, et al. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2022. PMID: 35666982. doi:10.1200/JCO.21.01393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。